SAB Biotherapeutics, Inc. (SABS) NASDAQ

3.57

-0.22(-5.80%)

Updated at February 20 04:00PM

Currency In USD

Valuation

Market Cap35.1M
Enterprise Value30.87M
P/E Ratio2.03
PEG Ratio0.02
Price/Sales Ratio297.5
Price/Book Ratio0.23
Enterprise/Revenue94.9
Enterprise/EBITDA0.49

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterSeptember 30, 2025

Profitability

Profit Margin163.38
Operating Margin-376.57

Management Effectiveness

Return On Assets0.1
Return On Equity0.33

Income Statement

Revenue1.32M
Revenue/Share0.01
Gross Profit-3.47M
EBITDA-28.99M
Net Income-34.11M
Diluted EPS-3.68

Balance Sheet

Total Cash110.88M
Total Cash/Share10.4
Total Debt6.19M
Total Debt/Equity0.04
Current Ratio10.5
Book Value Per Share15.48

Price History

52-Week Change96.15
52-Week High6.6
52-Week Low1
Moving Average 50 Days3.96
Moving Average 200 Days2.76

Statistics

Average Volume350,158
Shares Outstanding9.56M
% Held by Institutions169.79

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor1:10
Last Split DateJanuary 05, 2024